Mirum Pharmaceuticals MIRM 深 沪
等待开盘 10-15 09:30:00 美东时间
79.96
+0.340
+0.43%
华盛通- 最 高81.905
- 今 开78.41
- 成交量 97.51万股
- 最 低 78.35
- 昨 收 79.62
- 总市值 51.92亿
- 52周最高 130.00
- 市盈率 静 --
- 换手率 1.50%
- 52周最低 63.232
- 委 比 -76.48%
- 总股本 6493.22万
- 历史最高 130.00
- 量 比 1.02
- 振 幅 4.46%
- 历史最低 6.513
- 每 手 1
- 风险率 14.74%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Mirum Pharmaceuticals Reports Positive Phase 3 LIVMARLI Results
Mirum Pharmaceuticals ( ($MIRM) ) has issued an update. On October 12, 2026, Mi...
10-13 20:28
美股大行评级 | 潜在涨幅386.16%！摩根士丹利维持TeraWulf"超配"评级，上调目标价至65美元
今日重点评级关注：摩根士丹利：维持TeraWulf"超配"评级，目标价从62.5美元升至65美元；摩根士丹利：维持Hut 8"超配"评级，目标价从273美元升至275美元
10-13 12:30
Why Is Mirum Pharmaceuticals Stock Gaining Monday?
On Monday, Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) reported topline results from its Phase 3 EXPAND study evaluating LIVMARLI (maralixibat) to treat cholestatic pruritus in individuals aged six months and older suffering from ultra-rare cholestatic liver conditions, including biliary atresia. Foll...
10-12 21:38
Mirum Pharmaceuticals to report Livmarli trial results Monday
Mirum Pharmaceuticals (MIRM) said it will release topline results from a late-stage clinical trial of its Livmarli treatment on Monday, October 12, providing investors with a potential catalyst as the...
10-12 05:49
美股大行评级 | 潜在涨幅179.23%！奥本海默上调Aurora Innovation目标价至16美元，维持"跑赢大市"评级
今日重点评级关注：奥本海默：维持Aurora Innovation"跑赢大市"评级，目标价从15美元升至16美元；富国银行：维持Applied Digital"超配"评级，目标价从50美元升至55美元
10-09 16:25
RBC Capital Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $155
RBC Capital analyst Lisa Walter maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and raises the price target from $135 to $155.
10-08 22:55
Mirum Advances MRM-3379 With Completed Phase 1 ADME Study
Mirum Pharmaceuticals ($MIRM) announced an update on their ongoing clinical stu...
10-08 00:30
Baird Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $130
Baird analyst Brian Skorney maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and raises the price target from $123 to $130.
09-29 19:52
美股大行评级 | 潜在涨幅919.61%！HC Wainwright上调NeuroSense Therapeutics目标价至52美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持NeuroSense Therapeutics"买入"评级，目标价从8美元升至52美元；HC Wainwright & Co.：维持艾切托"买入"评级，目标价从27美元升至34美元
09-29 08:33
